

Special Issue

Membrane Receptors in Disease: Mechanisms and Targeted Therapeutic Strategies

Message from the Guest Editor

The critical role played by membrane receptors as therapeutic targets is well-established in a range of diseases, including cancer, autoimmune disorders, and neurodegenerative conditions. Our Special Issue aims to focus on the molecular mechanisms—such as genetic mutations, aberrant activation, and disrupted signaling pathways—underlying receptor-related pathogenesis. Key emphasis is placed on recent advances in the discovery and development of pharmaceutical agents designed to modulate receptor activity, including monoclonal antibodies, small-molecule inhibitors, bifunctional degraders, and allosteric modulators. This Special Issue focuses on the action of new and already known molecules in different study models, repositioned drugs, and ongoing studies of membrane receptor activity modulators. Authors are invited to submit their original articles, comprising basic research, clinical research, reviews, case studies, and other studies in this field.

Guest Editor

Prof. Dr. Robson Xavier Faria

1. Programa de Pós-Graduação em Ciências e Biotecnologia, Instituto de Biologia, Universidade Federal Fluminense, Rua Professor Marcos Waldemar de Freitas Reis, S/N, Niterói 24210-201, Brazil
2. Laboratório de Avaliação e Promoção da Saúde Ambiental, Instituto Oswaldo Cruz, Av. Brasil 4365, Rio de Janeiro 21040-360, Brazil

Deadline for manuscript submissions

31 March 2026



Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/255716

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us. We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)